Singapore: Sweden-based company NeuroVive Pharmaceutical's Asia arm has signed a collaboration agreement with Sanofi's affiliate for the development and commercialization of CicloMulsion in South Korea.

Under the agreement NeuroVive Asia will get an upfront payment, a conditional milestone payment and royalty on potential future sales in South Korea. CicloMulsion is being developed for the treatment of reperfusion injury in cardiovascular disease.

The NeuroVive Group is carrying out an extensive international program for the clinical development and commercialization of CicloMulsion ahead of the product's potential market launch.

"The collaboration with Sanofi will enable us to broaden the commercialization of CicloMulsion for the treatment of cardiovascular disease. South Korea is an important market in Asia and this collaboration with Sanofi is further confirmation of CicloMulsion's clinical and commercial potential. I look forward to a long and productive partnership with Sanofi, with the aim of launching CicloMulsion for the treatment of acute cardiovascular indications on the South Korean market," commented Mr Mikael Brönnegård, CEO, NeuroVive.